All Oncology News

Linda T. Vahdat, MD, discusses investigations of ADCs and targeted agents in patients with TNBC and residual disease following chemoimmunotherapy.

Researchers at Fox Chase Cancer Center have identified factors that could decrease incidence of prostate cancer in areas where rates are highest.

Ivonescimab has been granted priority review in China for the frontline treatment of patients with PD-L1–positive locally advanced or metastatic NSCLC.

The FDA granted priority review to durvalumab in limited-stage small cell lung cancer after platinum-based concurrent chemoradiotherapy.

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

Pirtobrutinib was safe and demonstrated activity in patients with Richter transformation, according to a subgroup analysis of the BRUIN trial.

Geoffrey Shouse, DO, PhD, discusses the benefits of utilizing targeted therapy approaches in the treatment of patients with follicular lymphoma.

A study led by experts at Roswell Park Comprehensive Cancer Center suggests that e-cigarette use may help some people quit using combustible cigarettes. 

The FDA has approved axatilimab for adult and pediatric patients with cGVHD who have progressed on at least 2 prior lines of systemic therapy.

The FDA has granted fast track designation to Deltacel in combination with low-dose radiation for pretreated metastatic non–small cell lung cancer.

Treatment with VP-315 led to reductions in tumor size in patients with basal cell carcinoma.

Durvalumab plus chemotherapy, then durvalumab with or without olaparib, was approved in Europe for select advanced/recurrent endometrial cancer.

AC699 has won fast track designation from the FDA for select patients with ER-positive, HER2-negative, ESR1-mutated breast cancer.

A new drug application has been submitted to the FDA for UGN-102 inlow-grade, intermediate-risk non–muscle-invasive bladder cancer.

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer.

Cannabis-related disorder was associated with the development of head and neck cancer in adults.

ASCO has released a research statement outlining 4 recommendations to decentralize clinical trials and improve patient access to these studies.

Linda T. Vahdat, MD, discusses the use of ADCs in metastatic TNBC and how neoadjuvant immunotherapy performs in patients with early-stage TNBC.

Mohamad Mohty, MD, PhD, discusses real-world data for elranatamab in relapsed/refractory multiple myeloma in the French compassionate use program.

Fox Chase Cancer Center announces Aitziber Buque Martinez, PhD, as an assistant professor in the Cancer Signaling and Microenvironment Research Program.

Enrollment will discontinue for the SELECT-AML-1 trial of tamibarotene/venetoclax/azacitidine in newly diagnosed, RARA-positive acute myeloid leukemia.

Trastuzumab deruxtecan earned conditional approval in China for HER2-positive gastric/gastroesophageal junction cancer after at least 2 lines of therapy.

Vebreltinib demonstrated preliminary activity in patients with non–central nervous system solid tumors harboring MET fusions.

Clinicians specializing in caring for patients with lung cancer discussed clinical trial updates on agents in stage III NSCLC.

Manali Kamdar, MD, discusses responses with liso-cel according to prior lines of therapy and BTK inhibitor exposure in mantle cell lymphoma.

A sNDA seeking the approval of toripalimab for frontline use in patients with unresectable or metastatic melanoma is under review by the NMPA.

The Nectin-4–directed antibody-drug conjugate 9MW2821 has received breakthrough therapy designation in China for pretreated, advanced urothelial carcinoma.

Kara N. Maxwell, MD, PhD, discusses the need to improve genetic testing rates for BRCA mutations in the male population.

Wearable-captured physiological metrics and electronic patient reported outcomes were practical and generated knowledge in Waldenström macroglobulinemia.

Atezolizumab plus bevacizumab showed efficacy in patients with hepatocellular carcinoma who had Child-Pugh B7 liver function.